Two weeks before the U.S. decides on its next president, the health-care industry’s finger-pointing over drug costs is heating up. Insurers and pharmacy benefit managers blame pharmaceutical companies. Drugmakers blame insurers. And have you seen how much money the hospitals spend?
Whether Hillary Clinton or Donald Trump wins on Nov. 8, most of the players are betting that something will get done on the cost of prescription drugs. They’re laying defensive and offensive groundwork for when new laws are drawn up by a Congress that has spent the last year holding hearings on the issue.